Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 29.99B, Biogen(BIIB) trades at $203.16. The stock has a price-to-earnings ratio of 22.42.
On 2026-07-21, Biogen(BIIB) stock traded between a low of $198.59 and a high of $203.70. Shares are currently priced at $203.16, which is +2.3% above the low and -0.3% below the high.
Biogen(BIIB) shares are trading with a volume of 652.82K, against a daily average of 1.81M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
BIIB News
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Biogen today and set a price target of $215.00. Claim 55% Off TipRanks Unlock powe...
Guggenheim analyst Yatin Suneja raised the firm’s price target on Biogen (BIIB) to $280 from $260 and keeps a Buy rating on the shares. The firm is revising som...
...
Analyst ratings
61%
of 36 ratingsMore BIIB News
Analysts are intrested in these 5 stocks: ( (BIIB) ), ( (BE) ), ( (FSLR) ), ( (OKLO) ) and ( (NNE) ). Here is a breakdown of their recent ratings and the ration...
Shares of Biogen BIIB were down 8.2% yesterday after the company presented data from the phase II CELIA study evaluating its experimental tau-targeting Alzheime...
Biogen (BIIB) announced the appointment of Michael Parini as chief legal officer, effective August 3. Parini will serve as a member of Biogen’s executive commit...
Eisai and Biogen recently reported that in the real-world three-year LEADER study, around 83% of early Alzheimer’s patients stayed stable or improved on LEQEMBI...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.